跳转至内容
Merck
CN

主要文件

查看所有文档

A6226

AM251

>98% (HPLC), solid, cannabinoid receptor (CB1) antagonist

别名:

1-（2,4-二氯苯基）-5-（4-碘苯基）-4-甲基-N-1-哌啶基-1H-吡唑-3-甲酰胺

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C22H21N4OCl2I
化学文摘社编号:
183232-66-8
分子量:
555.24
UNSPSC Code:
12352200
PubChem Substance ID:
24891069
NACRES:
NA.77
MDL number:
MFCD01861181
Assay:
>98% (HPLC)
Form:
solid
Quality level:
100
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

AM251, >98% (HPLC), solid

Quality Level

100

assay

>98% (HPLC)

form

solid

color

white

solubility

DMSO: >10 mg/mL, H2O: insoluble

originator

Sanofi Aventis

SMILES string

Cc1c(nn(-c2ccc(Cl)cc2Cl)c1-c3ccc(I)cc3)C(=O)NN4CCCCC4

InChI

1S/C22H21Cl2IN4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-7-16(23)13-18(19)24)21(14)15-5-8-17(25)9-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)

InChI key

BUZAJRPLUGXRAB-UHFFFAOYSA-N

Gene Information

mouse ... Cnr1(12801), Cnr2(12802)
rat ... Cnr1(25248)

Application

AM251，一种CB1 大麻素受体拮抗剂，已被用于一项研究，以确定其与海马神经元的相互作用，以增强小鼠的空间记忆。

Biochem/physiol Actions

AM251是一种CB1 大麻素受体拮抗剂。

Features and Benefits

《受体分类和信号转导》手册的大麻素受体页有该化合物的介绍。想要浏览手册的其他页面， 请单击此处。
该化合物由Sanofi Aventis开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

Other Notes

盐含量可能会有所不同。

hcodes

H413

Hazard Classifications

Aquatic Chronic 4

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
056M4611V
084M4610V
082M4621V
090M4624
098K46192

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Loren J Martin et al.
Current biology : CB, 29(2), 192-201 (2019-01-15)
Pain memories are hypothesized to be critically involved in the transition of pain from an acute to a chronic state. To help elucidate the underlying neurobiological mechanisms of pain memory, we developed novel paradigms to study context-dependent pain hypersensitivity in
Ramy Khella et al.
Psychopharmacology, 231(16), 3071-3087 (2014-04-08)
Whilst cannabinoid CB2 receptors were thought to exist predominantly in immune cells in the periphery, the recent discovery of CB2 receptors in the brain has led to an increased interest in the role of these central CB2 receptors. Several studies
Danilo De Gregorio et al.
Pain, 160(1), 136-150 (2018-08-30)
Clinical studies indicate that cannabidiol (CBD), the primary nonaddictive component of cannabis that interacts with the serotonin (5-HT)1A receptor, may possess analgesic and anxiolytic effects. However, its effects on 5-HT neuronal activity, as well as its impact on models of
查看所有相关文献

全球贸易项目编号

货号GTIN
A6226-10MG04061833381885
A6226-50MG04061833381892